- Home
- CWH vs GYRE Comparison
CWH vs GYRE Comparison
Compare CWH & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWH
- GYRE
- Stock Information
- Founded
- CWH 1966
- GYRE 2002
- Country
- CWH United States
- GYRE United States
- Employees
- CWH N/A
- GYRE N/A
- Industry
- CWH Retail-Auto Dealers and Gas Stations
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- CWH Consumer Discretionary
- GYRE Health Care
- Exchange
- CWH Nasdaq
- GYRE Nasdaq
- Market Cap
- CWH 1.1B
- GYRE 897.1M
- IPO Year
- CWH 2016
- GYRE N/A
- Fundamental
- Price
- CWH $14.98
- GYRE $7.23
- Analyst Decision
- CWH Strong Buy
- GYRE Strong Buy
- Analyst Count
- CWH 9
- GYRE 1
- Target Price
- CWH $21.22
- GYRE $18.00
- AVG Volume (30 Days)
- CWH 1.9M
- GYRE 88.7K
- Earning Date
- CWH 10-27-2025
- GYRE 11-12-2025
- Dividend Yield
- CWH 3.27%
- GYRE N/A
- EPS Growth
- CWH N/A
- GYRE N/A
- EPS
- CWH N/A
- GYRE 0.02
- Revenue
- CWH $6,318,924,000.00
- GYRE $102,189,000.00
- Revenue This Year
- CWH $4.92
- GYRE $16.80
- Revenue Next Year
- CWH $7.08
- GYRE $50.29
- P/E Ratio
- CWH N/A
- GYRE $429.99
- Revenue Growth
- CWH 5.15
- GYRE N/A
- 52 Week Low
- CWH $11.17
- GYRE $6.11
- 52 Week High
- CWH $25.97
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- CWH 36.54
- GYRE 43.54
- Support Level
- CWH $15.38
- GYRE $7.20
- Resistance Level
- CWH $16.78
- GYRE $7.44
- Average True Range (ATR)
- CWH 0.63
- GYRE 0.25
- MACD
- CWH -0.16
- GYRE -0.01
- Stochastic Oscillator
- CWH 5.66
- GYRE 18.61
About CWH Camping World Holdings Inc.
Camping World Holdings Inc is a retailer of RVs and related products and services. The company has two reportable segments; the Good Sam Services and Plans segment, which includes the sale of emergency roadside assistance plans; commissions on property and casualty insurance programs; travel assist programs; extended vehicle service contracts; vehicle financing and refinancing assistance; consumer shows and events; and consumer publications and directories; and the RV and Outdoor Retail segment, which generates maximum revenue and includes the sale of new and used RVs; commissions on the finance and insurance contracts related to the sale of RVs; the sale of RV service and collision work; the sale of RV parts, accessories, business to business distribution of RV furniture, etc.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.